levation of cardiac biomarkers has been shown to occur in 5-40% of cases after otherwise successful percutaneous coronary intervention (PCI). 1-3 Even mild myocardial damage with elevation of cardiac troponin T (TnT) or creatine kinase myocardial isozyme (CK-MB) is associated with increased risk of subsequent cardiac events, [3] [4] [5] [6] [7] and several strategies have been proposed to address this issue. [8] [9] [10] [11] Hydroxy-3-methylglutaryl co-enzyme A reductase inhibitors (statins) reportedly reduce myocardial injury during PCI and subsequent cardiovascular events. [12] [13] [14] [15] [16] [17] With the current wide use of drug-eluting stents to provide full coverage of coronary lesions, longer stents are necessary to prevent re-stenosis and thus more myocardial injury may occur during PCI with stenting. We performed a randomized controlled study of patients with stable angina to compare periprocedural myocardial damage with intensive or moderate lipid-lowering intervention before PCI 
Cordis, Miami Lakes, FL, USA) were implanted in all patients according to standard techniques. All patients received aspirin 100 mg/day and ticlopidine 200 mg/day for ≥3 days before stenting. All patients received a 70 IU/kg intravenous bolus of unfractionated heparin just before PCI. Additional heparin boluses were given to maintain activating clotting time (ACT) >300 s. Angiographic measurements were performed using an automated ACOM PC v3.1 computer-based system (Siemens Medical Systems, Tokyo, Japan). Intravascular ultrasonography (IVUS) was performed using motorized pullback at a constant speed of 0.5 mm/s during PCI. Angiographic success was defined as a final angiographic residual stenosis of <10% on visual estimation. Quantitative coronary angioplasty (QCA) and IVUS were performed by the laboratory section of the hospital, with investigators unaware of patient status. Angiographic complications, including side branch occlusions, arterial dissection, thrombus formation, slow -no reflow and distal embolization, did not occur in any cases.
Cardiac Enzyme Measurements
CK-MB and TnT levels were assessed serially before and 6, 12 and 24 h after PCI using an electrochemiluminescent immunoassay (ECLIA) (Roche, Tokyo, Japan). All TnT levels before PCI were 0 ng/ml and baseline CK-MB was within normal limit at ≤7.5 ng/ml.
Definitions
Late loss was considered as the difference between minimum lumen diameter (MLD) after PCI and MLD at 6 months. Restenosis was defined as ≥50% stenosis (by diameter) at follow-up. Frequency of major adverse cardiac events (MACEs) was determined as the cumulative frequency of death, MI, emergency coronary artery bypass graft surgery and ischemia-driven target lesion revascularization (TLR).
Study Endpoints
The primary endpoint of this study was the rate of small myocardial injury during PCI with stenting, defined as a postprocedural increase in TnT to >0.01 ng/ml. The secondary endpoint was CK-MB above the upper limit of normal (ULN) or >3× ULN, and occurrence of all MACE (death, MI or need for unplanned revascularization), restenosis, TLR from time of PCI until follow-up after 6 months.
Statistical Analysis
We enrolled 42 patients and divided them into 2 groups (Group A: n=21, Group B: n=21). Continuous variables are presented as a mean value ± standard deviation, with subgroup differences assessed using Student's t-test. Categorical variables are presented as counts and/or percentages, with differences between subgroups assessed using Fisher's exact test. Statistical significance was assumed for 2-sided values of p<0.05.
Results

Baseline Characteristics
Demographic data are summarized in Table 1 . No significant differences in background data were identified between the groups. Total cholesterol was reduced by 32% in Group A and 20% in Group B (p<0.05). LDL-C was reduced by 43% in Group A and 20% in Group B (p<0.05). Duration of statin treatment did not differ significantly between groups, and no adverse effects of statin therapy were observed. All patients took aspirin and ticlopidine for 6 months.
Angiographic Outcome and IVUS Analysis
QCA and IVUS data are presented in Table 2 . No significant differences in lesion location or lesion type were noted between groups. IVUS analysis detected no lipid-rich images, dissections or intramural hematomas during PCI. Angiographic success was reached in 100% of patients in each group, and side branch occlusion, thrombus, or slowflow after PCI did not occur in either group. Results of PCI, stent length and maximum balloon pressure were also similar between groups. There were also no statistical differences in balloon inflation time and balloon-to-artery ratio (data not shown). Anticoagulant therapy was continued as described previously without side-effect and the ACT level were maintained >300 ms during procedure.
Periprocedual Increases in Cardiac Markers
CK-MB and TnT changes during PCI are presented in Table 3 . CK-MB elevation to >ULN occurred in 4 patients in Group A (19%) and 7 patients in Group B (33.3%; p= 0.484). CK-MB elevation to >3×ULN occurred in 2 patients in group A (9.5%) and 4 patients in group B (19%; p=0.66). TnT >0.01 ng/ml was identified in 3 patients in Group A (14.2%) and 10 patients in Group B (47.6%; p=0.043). There was no statistical correlation between LDL-C level and the amount of cardiac enzymes in patients with cardiac damage incurred during procedure, and none between the dose of statin and the amount of cardiac enzyme in patients with cardiac damage.
Angiographic and Clinical Follow-up
The angiographic data at 6 months are shown in Table 4 . No significant differences were noted between groups. One patient in Group A died of cancer. At 6-month follow-up, no differences in MACE or TLR were noted between groups.
Discussion
Administration of stains is necessary in patients with cardiovascular problems, and these agents have beneficial effects on myocardial damage incurred during PCI. We have begun using Sirolimus-eluting stents in all patients undergoing elective PCI, [15] [16] [17] but to prevent re-stenosis, we implant longer stent and use high-pressure ballooning to avoid mal-apposition and poor expansion of the stents. Thus, elevation of cardiac enzymes, including very minor leaks of TnT, may occur in more cases. We thought that statin administration alone would not be sufficient to reduce the risk of cardiac damage during elective PCI, but the present results are the first from a prospective, randomized trial to indicate that compared with moderate lipid-lowering therapy intensive lipid-lowering therapy decreases the frequency of myocardial injury during PCI. TnT has better sensitivity and specificity for detecting minor myocardial damage than changes in CK-MB, so in the present study TnT >0.01 ng/ml was defined as minor myocardial damage. CK-MB elevation >3× ULN was also used as the generally accepted cut-off to signify periprocedural MI. 2 Furthermore, CK-MB elevation above ULN was used to indicate minor myocardial damage. Elucidating the mechanisms of the effects of statin therapy is difficult. According to previous reports, statins exert antiinflammatory effects, antithrombogenic effects and beneficial effects on endothelial function beyond merely decreasing cholesterol levels. [18] [19] [20] [21] [22] [23] [24] [25] The pleiotropic effects of statins are supported by numerous in vitro and in vivo studies, and such effects are obviously beneficial in limiting myocardial damage during PCI. 18, [26] [27] [28] [29] In our study, given that both groups received statin pharmacotherapy, we could not find a difference between the dose of statin and cardiac damage. Only intensive lipid-lowering was statically correlated with reducing myocardial damage during PCI, which may indicate that lipid lowering is more important than the pleiotropic effect of the clinical dose of statin.
As for the 6-month follow-up after PCI, no clinical or angiographic differences were apparent between groups. Sirolimus-eluting stent deployment decreased the risk of coronary events. However, evaluating the effects of statins in this small study was difficult and further studies are required to precisely elucidate the mechanisms of statins in the short-and long-term beneficial effects.
In conclusion, the present study shows that intensive lipid-lowering therapy rather than moderate lipid-lowering therapy before PCI may reduce periprocedural myocardial damage. 
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